Abbvie 4Q Results

Abbvie
4Q Revenues: $15.1 billion (+2%)
4Q Earnings: $2.5 billion (-39%)
FY Revenues: $58.1 billion (+3%)
FY Earnings: $11.8 billion (+3%)
Comments: Global revenues from the immunology portfolio were $7.9 billion in the quarter, up 18%. Humira sales were $5.6 billion, up 5%. U.S. Humira sales were $5.0 billion, an increase of 10% percent, while international sales were $573 million, down 27% due to biosimilar competition. Skyrizi sales were $1.6 billion, up 76%. Rinvoq sales were $770 million, up 49%.
 
Global revenues from the hematologic oncology portfolio were $1.6 billion in the quarter, down 13%. Imbruvica sales were $1.1 billion, down 20%, with U.S. sales of $841 million and international profit sharing of $274 million. Venclexta sales were $516 million, up 6%.
 
Global revenues from the neuroscience portfolio were $1.7 billion, an increase of 3%. Botox Therapeutic sales were $728 million, up 9%. Vraylar sales were $565 million, an increase of 16%. Ubrelvy sales were $197 million, up 8%.
 
Global revenues from the aesthetics portfolio were $1.3 billion, down 9%. Botox Cosmetic sales were $642 million, up 3%. Juvederm sales were $322 million, down 25%.